Moreover, DYRK2 downregulation was associated with a significantly shorter disease-free survival and overall survival in these CRC patients, potentially as these patients are more likely to develop resistance to 5-FU treatment, resulting in poorer treatment outcomes and higher rates of recurrent or metastatic disease. Here, DYRK2 is linked to metastatic neoplasm.